



IFW

PATENT

Case Docket No. WILKG501AUS

Date: August 2, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Zhang, et al.
Appl. No. : 10/826,478
Filed : April 16, 2004
For : DRUG SCREENING METHOD
FOR THE TREATMENT OF
BRAIN DAMAGE
Examiner : Unknown
Group Art Unit : 1614

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 2, 2004

(Date)

Daniel Hart, Reg. No. 40,637

TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with nine (9) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Daniel Hart
Registration No. 40,637
Attorney of Record
Customer No. 20,995
(619) 235-8550

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Zhang, et al.
App. No. : 10/826,478
Filed : April 16, 2004
For : DRUG SCREENING METHOD FOR THE
TREATMENT OF BRAIN DAMAGE
Examiner : Unknown
Group Art Unit : 1614

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing nine (9) references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,


KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Aug. 2, 2004

By: Daniel Hart

Daniel Hart
Registration No. 40,637
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
WILKG5.001AUSAPPLICATION NO.
10/826,478INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Zhang et al.FILING DATE
April 16, 2004GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	1 Aarts, M. et al. (2002) Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science. 298:846-850.
	2 Gong, X. et al. (1999) Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Trends. 20:191-196.
	3 Long, J. et al. (2003) Supramolecular structure and synergistic target binding of the N-terminal tandem PDZ domains of PSD-95. J. Mol. Biol. 327:203-214.
	4 Sattler, R. et al. (1999) Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 284:1845-1848.
	5 Sun, X. et al. (2003) N-methyl-D-aspartate receptor antagonist activity in traditional Chinese stroke medicines. Neurosignals. 12:31-38.
	6 Tochio, H. et al. (1999) Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide. Nature Structural Biology. 6(5):417-421.
	7 Tochio, H. et al. (2000) Solution structure and backbone dynamic of the second PDZ domain of postsynaptic density-95. J. Mol. Biol. 295:225-237.
	8 Tochio, H. et al. (2000) Formation of nNOS/PSD-95 PDZ dimer requires a preformed β -finger structure from the nNOS PDZ domain. 303:359-370.
	9 Zhang, M. et al. (2003) Organization of signaling complexes by PDZ-domain scaffold proteins. Acc. Chem. Res. 36:530-538.

S:\DOCS\CBW\CBW-2225.DOC\072604

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	